Lixisenatide- (BNF)- Anti-diabetic drug
Drug Name:
Lixisenatide- (BNF)- Anti-diabetic drug
List Of Brands:
Indication Type Description:
Indication:
Ref- BNF (British National Formulary- March 2015)
Indications-
Treatment of Type II diabetes
LIST OF APPROVED DRUG FROM 01-01-2015 To 31-12-2015
ISSUED BY NEW DRUG DIVISION - DRUG CONTROLLER GENERAL- INDIA
Sr.No Name of Drug Indication Date of Issue
3. Lixisenatide pre-filled solution 15-01-2015
for injection 10ug/20ug
For the treatment of adults with type 2 diabetes mellitus
to acheive glycaemic control in patients who are not
controlled by existing therapy:
In combination with the following oral antibiotics:
Metformin, a sulphonyl urea or a combination of these
agents.
In combination with a basal insulin:
alone, in combination with sulphonyl urea
Approved by DCG INDIA (Ref- DCGI approved List- 01-01-2015 To 31-12-3015)
Adverse Reaction:
Side effects-
nausea, vomiting, diarrhoea,dyspepsia
headache, dizziness, drowsiness, hypoglycaemia,
injection site reactions,
less commonly tachycardia, urticaria
Contra-Indications:
Contraindications-
ketoacidosis, severe gastro- intestinal disease
Cautions
Discontinue if symptoms of acute pancreatitis
severe abdominal pain
Renal impairment-
use with caution if eGFR 30-50 mL/minute /1.73M2
avoid if eGFR less than 30mL/minute/1.73m2
Dosages/ Overdosage Etc:
Ref- BNF (British National Formulary- March 2015)
BRAND - LYXUMIA
MANUFACTURER - SANOFI-AVENTIS
SANOFI-AVENTIS LTD
TEL- 0845 372 7101
uk-medicalinformation@sanofi-aventis.com
Indications-
Treatment of Type II diabetes
Dose-
By subcutaneous injection 50micrograms/mL
Pregnancy and lactation:
Pregnancy
avoid - toxicity in animal studies
women of child bearing age should use effective contraception
Breast feeding-
avoid- no information available